oxazolidin-2-one has been researched along with Arrhythmias, Cardiac in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farmer, HF; Johnson-Levonas, AO; Lai, E; Larson, P; Lauring, B; Li, XS; Liu, Y; Moreau, A; Wagner, JA | 1 |
| Alvey, C; Choo, HW; Cuozzo, C; Damle, B; Kirby, D; Labadie, RR; Riley, S | 1 |
2 trial(s) available for oxazolidin-2-one and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anticholesteremic Agents; Arrhythmias, Cardiac; Cholesterol Ester Transfer Proteins; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Investigational; Electrocardiography; Female; Fluoroquinolones; Heart; Humans; Male; Middle Aged; Models, Biological; Moxifloxacin; Oxazolidinones; Topoisomerase II Inhibitors; Young Adult | 2014 |
Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation.
Topics: Acetamides; Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Middle Aged; Moxifloxacin; Oxazolidinones; Quinolines; Young Adult | 2011 |